Guidance Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

Guidance Capital’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,388	Closed	-$528K	–	198
2024 Q3	$528K	Buy	10,388 +618	+6%	+$27.1K	0.17%	133
2024 Q2	$425K	Buy	9,770 +1,353	+16%	+$56.1K	0.14%	147
2024 Q1	$343K	Buy	8,417 +941	+13%	+$48.6K	0.13%	150
2023 Q4	$466K	Buy	7,476 +324	+5%	+$17K	0.19%	113
2023 Q3	$321K	Buy	7,152 +267	+4%	+$14.6K	0.14%	114
2023 Q2	$377K	Buy	+6,885	New	+$305K	0.16%	113

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Guidance Capital's AMPH Position: Q4 2024 in Review

Guidance Capital sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2024, closing a stake of 10,388 shares — an estimated $528K sold.

Guidance Capital first reported a position in AMPH in Q2 2023 and held it in 6 quarters. The position peaked at $528K in Q3 2024. 263 funds tracked by Wall St. Rank hold AMPH as of Q4 2024.

Guidance Capital reported no remaining Amphastar Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Guidance Capital sold 10,388 Amphastar Pharmaceuticals shares in Q4 2024, an estimated $528K.
Guidance Capital first reported a position in Amphastar Pharmaceuticals in Q2 2023 and held it in 6 quarters.
Guidance Capital's Amphastar Pharmaceuticals position peaked at $528K in Q3 2024.
263 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2024.

Based on Guidance Capital's 13F filing for Q4 2024, filed 27 Jan 2025.